Northern New England Accountable Care Collaborative selects Gold Standard Drug Database
- 06 Nov 2012
Elsevier's Gold Standard, a drug information provider, has announced that the Northern New England Accountable Care Collaborative, LLC, (NNEACC) has selected the Gold Standard Drug Database to deliver current and accurate drug data and drug decision support. Co-founded by Dartmouth Hitchcock, Eastern Maine Healthcare Systems, Maine Health and Dartmouth College, NNEACC develops, implements and evaluates new models of clinical care required to deliver on the Triple Aim â€“ better care, better health at lower cost.
The integration of the Gold Standard Drug Database module will allow the NNEACC to streamline and automate the process of integrating prescribing data with administrative and clinical information to provide a robust view of patient activity to clinicians.
The Gold Standard Drug Database will offer NNEACC drug pricing updates, therapeutic groupings of drug products, brand versus generic identifiers, and accurate information on generics. The Gold Standard Drug Database interacts intelligently with patient prescribing data to guide the clinician to an efficient and effective delivery of the patient's medication, assisting adherence to drug therapy for best health benefits. NNEACC will benefit from the database's modern technical architecture, combined with current, accurate content and built-in human logic for superior decision support, which distinguishes Gold Standard Drug Database from other drug compendia.
Led by Dr. David Wennberg, the NNEACC solution integrates administrative and clinical data sources in a proven data technology foundation with innovative analytics to provide focused and actionable information that supports clinicians and administrators as they manage care.
Elsevier / Gold Standard revamp Drug Class Overviews to address changing needs of healthcare professionals
- 23 Aug 2012
Drug information provider Elsevier / Gold Standard, US, has announced its new Drug Class Overviews, making Clinical Pharmacology more valuable at the point of care.
Clinical Pharmacology Drug Class Overviews are now even more powerful for evaluating formulary decisions and therapeutic drug substitutions. Elsevier / Gold Standard has improved the speed and usability of the content through bulleted summaries and tables, highlighting a variety of critical areas in drug-interaction information.
The new Drug Class Overviews includes a summary in simple bullet format; Pharmacology/Mechanism of Action with key pharmacology and pharmacokinetics and tables to highlight differences; Therapeutic Use, highlighting place in therapy, alternatives within a class, and key clinical differences with labeled, off-label, and not recommended indications; Comparative Efficacy, highlighting randomized control trials for one or more indications; Adverse Reactions/Toxicities summarizes serious adverse events and toxicities; Drug Interactions, helping clinicians determine which drugs to use; and Safety Issues, highlighting all contraindications and indicates BBWâ€™s, REMS, or MedGuides.
Elsevier / Gold Standard uses innovative technologies to provide a complete suite of drug information and decision support solutions. With a tenacious commitment to product quality, Elsevier / Gold Standard solutions empower healthcare organisations, professionals and consumers to meet the most pressing healthcare challenges, improve patient safety and ensure optimal outcomes.
Eaton Apothecary selects PAC from Elsevier / Gold Standard and Glass Box Analytics
- 29 Jun 2012
Drug information provider Elsevier / Gold Standard, US, has announced that Holliston, Massachusetts-based pharmacy chain Eaton Apothecary has purchased the new Predictive Acquisition Cost (PAC), developed by Glass Box Analytics and exclusively sold by Elsevier / Gold Standard.
Introduced earlier this year, PAC is a new drug price type that more closely tracks true acquisition cost. PAC employs predictive analytics techniques to estimate acquisition cost considering various factors, including MAC benchmarks, published price lists, existing price benchmarks, drug dispensing metrics, supply-demand measures, and survey-based acquisition costs. Independent tests show that PAC tracks drug acquisition cost with sufficient accuracy to support pricing activity.
Eaton Apothecary has 16 locations, including traditional retail pharmacies and those focused on home delivery and specialised care. As a classic community-centered pharmacy, Eaton Apothecary prides itself for its commendable one-on-one service with patients. With a reputation in the industry as an early-adopter of new, enhanced technologies and marketplace trends, Eaton Apothecary selected PAC, adding to the companyâ€™s competitive edge.
The pharmacy chain plans to utilise PAC for reimbursement analysis, wholesaler request for proposal processes with standards for deviations from the PAC price type, and as a cash pricing base.
Elsevier / Gold Standard adds FSS pricing to enhance pricing analysis with ProspectoRx
- 04 Mar 2011
Elsevier / Gold Standard, a US-based developer of drug databases and medication management solutions, has announced several enhancements to its pricing tool, ProspectoRx. This includes the addition of Federal Supply Schedule (FSS) pricing to facilitate pricing analysis.
Other enhancements include multiple watch lists and enhanced price change notifications, a new label name search box for market class, along with an improved interface, help tab, and report download capabilities.
The rate and frequency at which drug prices change in today's competitive environment make current, accurate and easily accessible pricing information critical to success in the pharmaceutical industry, it has been observed. The addition of FSS pricing is projected to make ProspectoRx an even more comprehensive pricing and analytics tool by providing immediate access to competitive federal pricing, better marketplace knowledge and less time spent researching.
Derived from Elsevier / Gold Standard's Alchemy drug product and pricing files, ProspectoRx is said to include extensive information on brand and generic drugs, delivering immediate access to price changes and new product information. Pricing information that is already offered includes: reported Average Wholesale Price (AWP), Wholesale Acquisition Cost (WAC), Direct Price (DP), and Federal Upper Limit (CMS-FUL), as well as Calculated Average Wholesale Price (C-AWP) 1.20 and 1.25, and Calculated Federal Upper Limit (C-CMS-FUL).
Search for more Pricing tools
To access our daily STM news feed through your iPhone, iPad, or other smartphones, please visit www.myscoope.com for a mobile friendly reading experience.
Gold Standard/Elsevier to continue publishing transparent drug pricing information
- 19 May 2010
Drug decision support provider Gold Standard/Elsevier, US, has announced that it will continue to publish transparent drug pricing information, including average wholesale price (AWP) and all other current and future pricing benchmarks. The announcement comes amidst statements by other drug database suppliers indicating they will discontinue publishing AWP in 2011.
Gold Standard/Elsevier supports transparent price benchmarks for payers (health plans, patients, government agencies and employers), pharmacies and other providers for prescription drugs. The company publishes reported and calculated drug prices that are clearly distinguished within the database, and adheres to strict internal policies for populating reported versus calculated pricing fields. Drug company reported prices of AWP, WAC (wholesale acquisition cost), CMS FUL (Federal Upper Limit), and Direct Price are included in Gold Standardâ€™s database.
Gold Standard/Elsevier provides comprehensive drug pricing data via its Alchemy integrated drug database and ProspectoRx web-based drug pricing and analysis tool. Both sources offer the most frequent and accurate updates in the industry. Following review and confirmation by editorial professionals, price changes are published â€˜liveâ€™ throughout the day as they are reported by drug companies. The companyâ€™s unique Price Change Indicator tracks pricing change catalysts consistently, reporting on whether the source came from the drug companyâ€™s reports, billing unit changes or errors.
Search for more decision support tools